Ramipril Capsule
Product Images NDC 0054-0106

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Ramipril (NDC 0054-0106). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fpl-bl-10mg-100caps-07.jpg (Fpl Bl 10mg 100caps 07)

Label for Ramipril Capsules USP 10 mg shows the active ingredient strength of 10 mg per capsule. The label includes the NDC 0054-0109-25 and indicates packaging of 100 capsules. Distributed by Hikma Pharmaceuticals USA Inc., Berkeley Heights, NJ. The label also features dosage and storage instructions along with a barcode.*

FDA Label Image

Fpl-bl-1pt25mg-100caps-07.jpg (Fpl Bl 1pt25mg 100caps 07)

Label for Ramipril Capsules USP, 1.25 mg, distributed by Hikma Pharmaceuticals USA Inc. The label indicates the package contains 100 capsules. It provides storage instructions and safety warnings, including keeping out of reach of children and dispensing in a child-resistant container. The label includes the NDC 0054-0106-25 and a barcode.*

FDA Label Image

Fpl-bl-2pt5mg-100caps-07.jpg (Fpl Bl 2pt5mg 100caps 07)

Ramipril Capsules, USP 2.5 mg oral capsules packaging label showing a 100 count bottle. The label includes dosing instructions, storage conditions, and child-resistant container warnings. Distributed by Hikma Pharmaceuticals USA Inc., Berkeley Heights, NJ. The NDC number 0054-0107-25 is displayed alongside a barcode.*

FDA Label Image

Fpl-bl-5mg-100caps-07.jpg (Fpl Bl 5mg 100caps 07)

Label of Ramipril Capsules, USP 5 mg oral capsules, 100 count, distributed by Hikma Pharmaceuticals USA Inc. The label includes storage instructions, dosage advice to consult package insert, and child-resistant container warning. The label also displays the NDC 0054-0108-25 and a barcode.*

FDA Label Image

Ramipril Figure 01

A line graph depicting the proportion of patients over days of follow-up comparing Ramipril with placebo. The x-axis represents days of follow-up ranging from 0 to about 1800, while the y-axis shows the proportion of patients from 0.00 to 0.20. Two lines are shown: a solid line for Ramipril and a dashed line for placebo, with Ramipril having a lower proportion of patients over time. The graph includes a p-value of 0.0001 indicating statistical significance between the groups.*

FDA Label Image

Ramipril Figure 02

A forest plot chart showing relative risk in the Ramipril group compared to placebo across various patient subgroups. The chart lists the number of patients and incidence of composite outcomes in the placebo group by categories including cardiovascular disease, diabetes, age, sex, hypertension, coronary artery disease history, prior myocardial infarction, cerebrovascular disease, peripheral vascular disease, and microalbuminuria. Confidence intervals are depicted as horizontal lines with black squares representing relative risk point estimates.*

FDA Label Image

Ramipril Structural Formula

Chemical structure of Ramipril, illustrating its molecular components including ester, amide, and carboxylic acid functional groups with stereochemistry indicated by wedge bonds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.